PHILADELPHIA – University of Pennsylvania School of Medicine researchers, along with colleagues at the University of Washington and the University of Toronto, have received $8 million for stem-cell research. The Penn group is one of nine research hubs awarded $170 million over the next seven years by the National Heart, Lung, and Blood Institute (NHLBI) to develop the high-potential field of stem- and progenitor-cell tools and therapies.
The awards create the NHLBI Progenitor Cell Biology Consortium, which will bring together researchers from the heart, lung, blood, and technology research fields. The consortium assembles multidisciplinary teams of principal investigators and an administrative coordinating center to focus on progenitor cell biology.
While a stem cell can renew itself indefinitely or differentiate, a progenitor cell can only divide a limited number of times and is often more limited than a stem cell in the kinds of cells it can become. Given the potential of these cells for clinical applications, the goals of the consortium are to identify and characterize progenitor cell lines, direct the differentiation of stem and progenitor cells to desired cell fates, and develop new clinical strategies to address the unique challenges presented by the transplantation of these cells.
The grant’s principal investigator Edward Morrisey, PhD, Professor of Medicine and Cell and Developmental Biology and Scientific Director of the Penn Institute for Regenerative Medicine, and colleagues will determine how certain signaling pathways — ordered sequences of biochemical reactions inside cells — affect cardiac and blood-forming cell development and cardiac regeneration and repair. The team will also study whether these pathways, namely Wnt and Notch, may be harnessed for therapeutic applications.
For more information on the NHLBI awards go to: http://www.nih.gov/news/health/oct2009/nhlbi-07.htm
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.